Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00884598
Other study ID # CDR0000636508
Secondary ID HUMCM-CIRABEUDRA
Status Completed
Phase Phase 1
First received
Last updated
Start date December 2008
Est. completion date October 2012

Study information

Verified date May 2024
Source Universitätsmedizin Mannheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Cilengitide may stop the growth of brain metastases by blocking blood flow to the tumor. Radiation therapy uses high energy X-rays to kill tumor cells. Giving cilengitide together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of cilengitide when given together with whole-brain radiation therapy in treating patients with brain metastases from lung cancer.


Description:

OBJECTIVES: - Primary - To assess the safety and tolerability of daily cilengitide by determining its dose-limiting toxicity and maximum-tolerated dose when combined with concomitant fractionated whole-brain radiation therapy in patients with brain metastases from lung cancer. - Secondary - To collect evidence of the best overall response rate, overall survival, brain-specific progression-free survival, and tumor-specific progression-free survival of these patients. - To collect evidence of changes in functional MRI imaging studies at 6 and 12 weeks after initiation of therapy. - To collect evidence of early response by functional MRI (ASL technique) on days 1, 4, and 12, immediately before and after the administration of cilengitide. - To collect evidence of changes in neurological and neurocognitive function tests at 6 and 12 weeks after initiation of therapy. - To further evaluate the safety and toxicity of the combination of cilengitide and whole-brain radiation therapy. - To further evaluate the pharmacokinetics of cilengitide administered daily. OUTLINE: Patients receive oral cilengitide once daily and undergo whole-brain radiotherapy on the same days. Treatment continues for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on days 1, 4, 5, and 12 for pharmacokinetic studies. After completion of study treatment, patients are followed for 10 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed lung cancer (small cell or non-small cell lung cancer) - Patient must be eligible for whole-brain radiotherapy - Presence of brain metastasis (single or multiple, synchronous or metachronous) from lung cancer not amenable to surgery or radiosurgery (presence of metastases at any other site is allowed) - No leptomeningeal metastasis or known subarachnoid spread of tumor PATIENT CHARACTERISTICS: - ECOG performance status (PS) 0-1 (ECOG PS 2 allowed if due to the presence of cerebral metastases and not due to a high peripheral-tumor load or other reasons) - Life expectancy = 3 months - Adequate hematologic function - Total bilirubin < 1.5 times upper limit of normal (ULN) - AST, ALT, and alkaline phosphatase < 2.5 times ULN - Creatinine clearance > 60 mL/min - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after completion of study treatment - No history of acute or chronic renal disease - No other malignancies treated within the past 5 years, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin - No uncontrolled hypertension - No history of coagulation disorder associated with bleeding or recurrent thrombotic events - No peptic ulcer disease within the past 6 months - No congestive heart failure, high risk for uncontrolled arrhythmia, or history of clinically significant coronary heart disease - No known alcohol or drug abuse - No other significant or acute concomitant disease - No dementia or altered mental status PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Concurrent corticosteroids allowed if the dosing regimen has ben stable = 5 days - Concurrent anticonvulsants allowed if the dosing regimen has been stable for the past week - More than 30 days since prior participation in another clinical trial - No concurrent anticoagulation with vitamin K antagonists, therapeutic-dose anticoagulation with heparin resulting in prolonged PTT, or therapeutic-dose anticoagulation with low molecular weight heparin (low-dose [i.e. prophylactic], low molecular weight heparins allowed) - No prior whole-brain radiation or radiosurgery - No prior antiangiogenic therapy - No other concurrent anticancer therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cilengitide

Other:
pharmacological study

Radiation:
radiation therapy


Locations

Country Name City State
Germany University Medical Center, Department of Surgery Mannheim

Sponsors (2)

Lead Sponsor Collaborator
Universitätsmedizin Mannheim Heidelberg University

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (i) Any grade III-IV non-hematological toxicity as defined by CTCAE, version 3.0, with the exclusion ofalopecia, nausea, vomiting, and fever that can be rapidly contolled with appropriate measures; (ii) absolute neutrophil count (ANC)<0.5x10'/L lasting for >7days; (iii) febrile neutropenia defined as ANC <1.0x10'/L and fever >38.5°C; (iv) platelets <25x10'/L or thrombocytopenic bleeding requiring transfusion; and (v) severe hypotension requiring dopamine administration. 12 days
Primary Maximum-tolerated dose 5 planned steps to be tested: 100, 250, 500, 750, to 1000mg; the highest dose at which one or no DLT will have been observed among 6 patients 12 days
Secondary Overall response rate Any response to treatment 12 weeks
Secondary Overall survival Death as event, Kaplan-Meier (KM) 1 year
Secondary Brain-specific progression-free survival (PFS) Every recurrence within the brain or death is an event, Kaplan-Meier (KM) 1 year
Secondary Tumor-specific PFS Every tumor related event or death will be counted, Kaplan-Meier (KM) 1 year
Secondary Changes in functional MRI imaging (time to peak) at 6 and 12 weeks time-to-peak measurements 12 weeks
Secondary Changes in functional MRI imaging (blood flow) at 6 and 12 weeks blood flow measurements 12 weeks
Secondary Changes in functional MRI imaging (blood volume changes) at 6 and 12 weeks blood volume changes during functional MRI 12 weeks
Secondary Evidence of early response by functional MRI on days 1, 4, and 12 (ASL technique) on day 1,4 and 12, immediately before and after the administration of cilengitide. 12 days
Secondary Changes of neurocognitive function tests (intelligence) at 6 and 12 weeks Intelligence was measured with a multiple-choice test of vocabulary knowledge. 12 weeks
Secondary Changes of neurocognitive function tests (memory figures) at 6 and 12 weeks Memory was tested by aims of "Medical College of Georgia Complex Figures" 12 weeks
Secondary Changes of neurocognitive function tests (memory verbal) at 6 and 12 weeks Memory was tested by aims of "Rea Auditory Verbal Learning Test - German Version" 12 weeks
Secondary Changes of neurocognitive function tests (perception) at 6 and 12 weeks Perception was assessed by the "Digit Symbol Substitution Test" 12 weeks
Secondary Changes of neurocognitive function tests (attention/alertness) at 6 and 12 weeks Attention was tested by "Alertness" 12 weeks
Secondary Changes of neurocognitive function tests (attention) at 6 and 12 weeks Attention was tested by "Divided Attention" 12 weeks
Secondary Changes of neurocognitive function tests (attention speaking) at 6 and 12 weeks Attention was tested by "Go,A.lo-Go". 12 weeks
Secondary Fatigue at 6 and 12 weeks "Functional Assessment of Cancer Therapy - Fatigue Subscale" measured in points (range 0-52) 12 weeks
Secondary Anxiety/depression at 6 and 12 weeks "Hospital Anxiety and Depression Scale - German Version" 12 weeks
Secondary Activities of daily living (Barthel) at 6 and 12 weeks "Barthel Activities of Daily Living Index" measured in points (range 0-100) 12 weeks
Secondary Activities of daily living (instrumental) at 6 and 12 weeks "lnstrumental Activities of Daily Living Scale" measured in points (range 0-8) 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk